Integrum AB (publ) (INTEG-B.ST)
SEK 13.28
(-1.34%)
SEK 13.28
(-1.34%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 690.56 Thousand SEK | -98.86% |
| 2022 | 60.84 Million SEK | 30.68% |
| 2021 | 46.55 Million SEK | 33.45% |
| 2020 | 34.88 Million SEK | 63.29% |
| 2019 | 21.36 Million SEK | 21.73% |
| 2018 | 17.55 Million SEK | 52.93% |
| 2017 | 11.47 Million SEK | -38.13% |
| 2016 | 18.54 Million SEK | 60.87% |
| 2015 | 11.53 Million SEK | 1.32% |
| 2014 | 11.38 Million SEK | -25.99% |
| 2013 | 15.37 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 16.19 Million SEK | 988.1% |
| 2023 Q2 | 20.64 Million SEK | 12.75% |
| 2023 FY | 690.56 Thousand SEK | -98.86% |
| 2023 Q1 | 18.3 Million SEK | 24.49% |
| 2023 Q4 | -1.82 Million SEK | -130.0% |
| 2023 Q3 | 6.08 Million SEK | -70.55% |
| 2022 Q2 | 17.43 Million SEK | 10.37% |
| 2022 Q1 | 15.79 Million SEK | -2.71% |
| 2022 FY | 60.84 Million SEK | 30.68% |
| 2022 Q4 | 14.7 Million SEK | 14.02% |
| 2022 Q3 | 12.89 Million SEK | -26.04% |
| 2021 Q2 | 10.7 Million SEK | 2.2% |
| 2021 Q1 | 10.47 Million SEK | 17.55% |
| 2021 FY | 46.55 Million SEK | 33.45% |
| 2021 Q4 | 16.23 Million SEK | 78.72% |
| 2021 Q3 | 9.08 Million SEK | -15.16% |
| 2020 Q3 | 8.8 Million SEK | -16.6% |
| 2020 FY | 34.88 Million SEK | 63.29% |
| 2020 Q4 | 8.91 Million SEK | 1.18% |
| 2020 Q2 | 10.56 Million SEK | 60.05% |
| 2020 Q1 | 6.6 Million SEK | 23.34% |
| 2019 Q4 | 5.35 Million SEK | -14.57% |
| 2019 FY | 21.36 Million SEK | 21.73% |
| 2019 Q1 | 2.96 Million SEK | -17.12% |
| 2019 Q2 | 6.78 Million SEK | 128.44% |
| 2019 Q3 | 6.26 Million SEK | -7.62% |
| 2018 FY | 17.55 Million SEK | 52.93% |
| 2018 Q4 | 3.58 Million SEK | -14.83% |
| 2018 Q3 | 4.2 Million SEK | -40.09% |
| 2018 Q2 | 7.01 Million SEK | 155.68% |
| 2018 Q1 | 2.74 Million SEK | 1601.84% |
| 2017 Q1 | 5.69 Million SEK | 51.75% |
| 2017 FY | 11.47 Million SEK | -38.13% |
| 2017 Q4 | -182.79 Thousand SEK | -112.32% |
| 2017 Q3 | 1.48 Million SEK | -66.91% |
| 2017 Q2 | 4.48 Million SEK | -21.25% |
| 2016 Q3 | 4.5 Million SEK | 45.33% |
| 2016 Q1 | 7.19 Million SEK | 60.03% |
| 2016 FY | 18.54 Million SEK | 60.87% |
| 2016 Q2 | 3.09 Million SEK | -56.93% |
| 2016 Q4 | 3.75 Million SEK | -16.7% |
| 2015 Q4 | 4.49 Million SEK | 78.99% |
| 2015 Q3 | 2.51 Million SEK | 0.0% |
| 2015 FY | 11.53 Million SEK | 1.32% |
| 2014 FY | 11.38 Million SEK | -25.99% |
| 2013 FY | 15.37 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Acarix AB (publ) | 5.29 Million SEK | 86.963% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 99.77% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 99.77% |
| Arcoma AB | 11.07 Million SEK | 93.762% |
| Bactiguard Holding AB (publ) | 139.98 Million SEK | 99.507% |
| BICO Group AB (publ) | 1.83 Billion SEK | 99.962% |
| Boule Diagnostics AB (publ) | 249.71 Million SEK | 99.723% |
| CellaVision AB (publ) | 463.04 Million SEK | 99.851% |
| Clinical Laserthermia Systems AB (publ) | 2.99 Million SEK | 76.958% |
| Chordate Medical Holding AB (publ) | -28.41 Million SEK | 102.43% |
| C-Rad AB (publ) | 66.01 Million SEK | 98.954% |
| Duearity AB (publ) | -4.17 Million SEK | 116.529% |
| Dignitana AB (publ) | 58.97 Million SEK | 98.829% |
| Episurf Medical AB (publ) | -41.8 Million SEK | 101.652% |
| Getinge AB (publ) | 13.43 Billion SEK | 99.995% |
| Scandinavian Real Heart AB (Publ) | -50.21 Million SEK | 101.375% |
| Iconovo AB (publ) | 17.57 Million SEK | 96.071% |
| Luxbright AB (publ) | -2.79 Million SEK | 124.69% |
| Mentice AB (publ) | 236.38 Million SEK | 99.708% |
| OssDsign AB (publ) | 83.64 Million SEK | 99.174% |
| Paxman AB (publ) | 12.61 Million SEK | 94.527% |
| Promimic AB (publ) | 38.51 Million SEK | 98.207% |
| Qlife Holding AB (publ) | -50.75 Million SEK | 101.361% |
| SciBase Holding AB (publ) | 16.03 Million SEK | 95.694% |
| ScandiDos AB (publ) | 47.55 Million SEK | 98.548% |
| Sectra AB (publ) | 557.55 Million SEK | 99.876% |
| Sedana Medical AB (publ) | 108.98 Million SEK | 99.366% |
| Senzime AB (publ) | 8.33 Million SEK | 91.719% |
| SpectraCure AB (publ) | -9.22 Million SEK | 107.487% |
| Stille AB | 132.17 Million SEK | 99.478% |
| Vitrolife AB (publ) | 1.97 Billion SEK | 99.965% |
| Xvivo Perfusion AB (publ) | 416.91 Million SEK | 99.834% |